Novartis Ag (NVS)
$91.58 0.86 (0.95%)
18:59 EST NVS Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 213.45B
PE Ratio 26.86
Volume (Avg. Vol.) 1.32M
Day's Range 91.27 - 92.10
52-Week Range 69.18 - 99.84
Dividend & Yield 2.98 (3.25%)
NVS Stock Predictions, Articles, and Novartis Ag News
- From InvestorPlace
- From the Web
Novartis AG (NYSE:NVS) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS has a market value of $200.9 billion which is in the top decile in its industry group. The ranking for NVS by Portfolio Grader places it 45 among the 133 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 297 among the 782 companies in the sector, and number 2,089 in the nearly 5,000 company Portfolio Grader universe.
Currently, Novartis AG (NYSE:NVS) has a Hold using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for 2 months.
The current recommendation of Hold for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for the last month.
With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.
JUNO stock has a lot going for it, but a bullish position looks a good deal better when fully-immunized with an options hedge.
3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald’s Corporation (MCD) and Novartis AG (ADR) (NVS)
Boeing (BA) has won a dispute with Airbus, McDonald's (MCD) workers strike in the US and UK and Novartis (NVS) names Van Narasimhan its CEO.
Novartis (NVS) has garnered approval from the FDA for its groundbreaking cancer gene therapy, which will cost close to half a million.
United Therapeutics (UTHR) shares skyrocketed Friday amidst rumors that the company may be the subject of a takeover by a pharma giant soon.
Novartis (NVS) stock got a boost on Tuesday with the release of positive results in its earnings report for the second quarter of 2017.
Teva Pharmaceutical (TEVA) is perhaps the poster child for what can go wrong with an investment. But TEVA stock is cheap and could double in price.
Teva's recent migraine drug data, while positive, didn't impress investors. What happened, and should you tussle with TEVA stock?
Biotechnology is among the most exciting and lucrative sectors for investors, and these 3 biotech stocks stand out...
Valeant Pharmaceuticals flipped to a profit in Q1, and VRX stock is jumping by double digits. But Valeant's long-term issues haven't budged.
Valeant earnings are due out Tuesday morning, but it would take a laundry list of good news to sustain the rally in VRX stock.
I've uncovered a data set that show Switzerland as the most innovative country in the world. Here's how to take advantage...
Amgen (AMGN) reports Q4 earnings on Thursday, and if something does weigh on AMGN stock, it'll likely be one of these three factors.
Uncertainty, optimism and good liquidity are good reasons to consider an Amgen spread in lieu of AMGN stock in front of earnings.
Generic drugmakers Mylan (MYL), Teva (TEVA) and Novartis (NOV) took a hit from DOJ subpoenas on speculation of price-fixing in the industry.
Global Ophthalmic Lasers Market to Exhibit 5.3% CAGR and Hit USD 722.0 Million by 2026; Novartis Announces its FDA Approval to Perform Advanced Ophthalmic Surgeries: Fortune Business Insights™
Navellier RatingsPowered by Portfolio Grader